Overview

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

Status:
Terminated
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Cephalon
Collaborators:
H. Lundbeck A/S
The Parkinson Study Group